MiR-9 acts as an OncomiR in prostate cancer through multiple pathways that drive tumour progression and metastasis

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Seashols Williams, S J ^a   Budd, W ^a,b   Clark, G C ^a   Wu, Q ^a   Daniel, R ^a   Dragoescu, E ^a   Zehner, Z E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b American International Biotechnology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 9; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 5; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; MESSENGER RNA; MICRORNA; MIRN92 MICRORNA, HUMAN; SOCS5 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; LASER CAPTURE MICRODISSECTION; MALE; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; CELL MOTION; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; ONCOGENE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MICE; MICRORNAS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; ONCOGENES; PROSTATIC NEOPLASMS; RNA, MESSENGER; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84979556364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159601     Document Type: Article

References (58)

1. Key statistics of prostate cancer. American Cancer Society. 2015. Available: http://www.cancer.org/ cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics.
2. Ismail MT, Gomella LG. Transrectal prostate biopsy. Urol Clin North Am. 2013; 40(4): 457-72. doi: 10. 1016/j.ucl.2013.07.012 PMID: 24182969
3. Chen FZ, Zhao XK. Prostate cancer: Current treatment and prevention strategies. Iran Red Crescent Med J. 2013; 15(4): 279-84. doi: 10.5812/ircmj.6499 PMID: 24082997
4. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5): 843-54. PMID: 8252621
5. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4): 642-55. doi: 10.1016/j.cell.2009.01.035 PMID: 19239886
6. Zhang L, Stokes N, Polak L, Fuchs E. Specific microRNAs are preferentially expressed by skin stem cells to balance self-renewal and early lineage commitment. Cell Stem Cell. 2011; 8(3): 294-308. doi: 10.1016/j.stem.2011.01.014 PMID: 21362569
7. Pan Q, Chegini N. MicroRNA signature and regulatory functions in the endometrium during normal and disease states. Semin Reprod Med. 2008; 26(6): 479-93. doi: 10.1055/s-0028-1096128 PMID: 18951330
8. Wu S, Huang S, Ding J, Zhao Y, Liang L, Liu T, et al. Multiple microRNAs modulate p21Cip1/Waf1expression by directly targeting its 3' untranslated region. Oncogene. 2010; 29(15): 2302-8. doi: 10. 1038/onc.2010.34 PMID: 20190813
9. Thomas M, Lange-Grünweller K, Hartmann D, Golde L, Schlereth J, Streng D, et al. Analysis of transcriptional regulation of the human miR-17-92 cluster; evidence for involvement of pim-1. Int J Mol Sci. 2013; 14(6): 12273-96. doi: 10.3390/ijms140612273 PMID: 23749113
10. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated micro-RNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010; 12(3): 247-56. doi: 10.1038/ ncb2024 PMID: 20173740
11. Bertero T, Grosso S, Robbe-Sermesant K, Lebrigand K, Hénaoui IS, Puisségur MP, et al. "Seed-milarity" confers to hsa-miR-210 and hsa-miR-147b similar functional activity. PLoS One. 2012; 7(9): e44919. doi: 10.1371/journal.pone.0044919 PMID: 23028679
12. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23(20): 4051-60. PMID: 15372072
13. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10): 997-1006. doi: 10.1038/cr.2008.282 PMID: 18766170
14. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL. Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: Association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer. 1994; 58(5): 721-9. PMID: 8077059
15. Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Ware JL. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate. 1998; 34(4): 275-82. PMID: 9496902
16. Astbury C, Jackson-Cook CK, Culp SH, Paisley TE, Ware JL. Suppression of tumorigenicity in the human prostate cancer cell line M12 via microcell-mediated restoration of chromosome 19. Genes Chromosomes Cancer. 2001; 31(2): 143-55. PMID: 11319802
17. Liu X, Wu Y, Zehner ZE, Jackson-Cook C, Ware JL. Proteomic analysis of the tumorigenic human prostate cell line M12 after microcell-mediated transfer of chromosome 19 demonstrates reduction of vimentin. Electrophoresis. 2003; 24(19-20): 3445-53. PMID: 14595690
18. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979; 17(1): 16-23. PMID: 447482
19. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978; 21(3): 274-81. PMID: 631930
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001; 25(4): 402-8. PMID: 11846609
21. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA. 2004; 10(10): 1507-17. PMID: 15383676
22. Kruger J, Rehmsmeier M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res. 2006; 34(Web Server issue): W451-4. PMID: 16845047
23. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, et al. DIANA miRPath v.2.0: Investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012; 40 (Web Server issue): W498-504. doi: 10.1093/nar/gks494 PMID: 22649059
24. Wang X, El Naqa IM Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics. 2008; 24(3): 325-32. PMID: 18048393
25. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of micro-RNAs. Genome Res. 2009; 19(1): 92-105. doi: 10.1101/gr.082701.108 PMID: 18955434
26. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP. Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol 2011; 18(10): 1139-46. doi: 10.1038/nsmb.2115 PMID: 21909094
27. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1): 15-20. PMID: 15652477
28. Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M, et al. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J. 2009; 276(19): 5537-46. doi: 10.1111/j.1742-4658.2009.07237.x PMID: 19702828
29. Liu M, Zhu H, Yang S, Wang Z, Bai J, Xu N. C-myc suppressed E-cadherin through miR-9 at the posttranscriptional level. Cell Biol Int 2013; 37(3): 197-202. doi: 10.1002/cbin.10039 PMID: 23364919
30. Lu J, Luo H, Liu X, Peng Y, Zhang B, Wang L, et al. miR-9 targets CXCR4 and functions as a potential tumor suppressor in nasopharyngeal carcinoma. Carcinogenesis. 2014; 35(3): 554-63. doi: 10.1093/ carcin/bgt354 PMID: 24170200
31. Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, et al. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst. 2013; 105(22): 1750-8. doi: 10.1093/jnci/ djt302 PMID: 24168967
32. Sun Z., Han Q, Zhou N, Wang S, Lu S, Bai C, et al. MicroRNA-9 enhances migration and invasion through KLF17 in hepatocellular carcinoma. Mol Oncol. 2013; 7(5): 884-94. doi: 10.1016/j.molonc. 2013.04.007 PMID: 23684102
33. Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H. Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer. 2010; 9(16): 4598-16.
34. Wang J, Zhao H, Tang D, Wu J, Yao G, Zhang Q. Overexpressions of MicroRNA-9 and MicroRNA-200c in human breast cancers are associated with lymph node metastasis. Cancer Biother Radiopharm; 2013; 28(4): 283-288. doi: 10.1089/cbr.2012.1293 PMID: 23617747
35. Yu T, Liu K, Wu Y, Fan J, Chen J, Li C, et al. MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the wnt/beta-catenin signaling pathway. Oncogene. 2014; 33(42): 5017-27. doi: 10.1038/onc.2013.448 PMID: 24141785
36. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012; 31(17): 3513-23. doi: 10.1038/emboj.2012.183 PMID: 22773185
37. Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol. 2013; 14(5): 297-306. doi: 10.1038/nrm3567 PMID: 23594950
38. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008; 68(10): 3645-54. doi: 10. 1158/0008-5472.CAN-07-2938 PMID: 18483246
39. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 2001; 61(22): 8135-42. PMID: 11719442
40. Voronkov A, Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors. Curr Pharm Des. 2013; 19(4): 634-64. PMID: 23016862
41. Zhang X, Ladd A, Dragoescu E, Budd WT, Ware JL, Zehner ZE. MicroRNA-17-3p is a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate tumors analyzed by laser capture microdissection. Clin Exp Metastasis. 2009; 26(8): 965-79. doi: 10.1007/s10585-009-9287-2 PMID: 19771525
42. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: Determinants beyond seed pairing. Mol Cell. 2008; 27(1): 91-105.
43. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer. 2013; 12(86).
44. Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004; 114(4): 569-81. PMID: 15314694
45. Linossi EM, Chandrashekaran IR, Kolesnik TB, Murphy JM, Webb AI, Willson TA, et al. Suppressor of cytokine signaling (SOC5) utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein shc-1. PLoS One. 2013; 8(8): e70536. doi: 10.1371/journal.pone.0070536 PMID: 23990909
46. Krebs DL, Hilton DJ. SOCS proteins: Negative regulators of cytokine signaling. Stem Cells. 2001; 19 (5): 378-87. PMID: 11553846
47. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004; 15(2): 185-97. PMID: 15260970
48. Budd WT, Seashols-Williams SJ, Clark GC, Weaver D, Calvert V, Petricoin E, et al. Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis. PLoS One. 2015 Nov 6; 10(11):e0142373. doi: 10.1371/journal.pone.0142373 PMID: 26544868
49. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patients poor prognosis. RNA. 2008; 14(11): 2348-60. doi: 10.1261/rna.1034808 PMID: 18812439
50. Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, et al. Systematic Comparison of Microarray Profiling, Real-Time PCR, and Next-Generation Sequencing Technologies for Measuring Differential microRNA Expression. RNA. 2010; 16: 991-1006. doi: 10.1261/rna.1947110 PMID: 20360395
51. Liang H, Studach L, Hullinger RL, Xie J, Andrisani OM. Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b∼25. Exp Cell Res. 2014; 320(2):188-99. doi: 10.1016/j.yexcr.2013.09.020 PMID: 24135225
52. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA profiling of prostate cancer. J Cancer. 2013; 4(5): 350-7. doi: 10.7150/jca.6394 PMID: 23781281
53. Liu S, Kumar SM, Lu H, Liu A, Yang R, Pushparajan A, et al. MicroRNA-9 up-regulates E-cadherin through inhibition of NF-kappaB1-Snail1 pathway in melanoma. J Pathol. 2012; 226(1): 61-72. doi: 10. 1002/path.2964 PMID: 22131135
54. Gao F, Zhao ZL, Zhao WT, Fan QR, Wang SC, Li J, et al. miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells. Biochem Biophys Res Commun. 2013; 431(3): 610-6. doi: 10.1016/j.bbrc.2012.12.097 PMID: 23291181
55. Jin Z, Zhao C, Han X, Han Y. Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression. BMC Cancer. 2012; 12:480. doi: 10.1186/1471-2407-12-480 PMID: 23075330
56. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci. 1999; 112(Pt 8): 1237-45. PMID: 10085258
57. Babon JJ, Sabo JK, Zhang JG, Nicola NA, Norton RS. The SOCS box encodes a hierarchy of affinities for Cullin5: Implications for ubiquitin ligase formation and cytokine signaling suppression. J Mol Biol. 2009; 387(1): 162-74. PMID: 19385048
58. Budd WT. Combinatorial analysis of tumorigenic microRNAs driving prostate cancer. Doctoral dissertation, Virginia Commonwealth University. 2012. Available: http://scholarscompass.vcu.edu/cgi/ viewcontent.cgi?article=3847&context=etd.